BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 8129742)

  • 1. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
    Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
    Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
    Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
    Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes.
    Serradeil-Le Gal C; Raufaste D; Marty E; Garcia C; Maffrand JP; Le Fur G
    Biochem Biophys Res Commun; 1994 Feb; 199(1):353-60. PubMed ID: 8123034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
    Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
    J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin and oxytocin receptors on plasma membranes from rat mammary gland. Demonstration of vasopressin receptors by stimulation of inositol phosphate formation, and oxytocin receptors by binding of a specific 125I-labeled oxytocin antagonist, d(CH2)5(1)[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT.
    Soloff MS; Fernström MA; Fernström MJ
    Biochem Cell Biol; 1989; 67(2-3):152-62. PubMed ID: 2546575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
    Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
    Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances.
    Kostrzewska A; Laudanski T; Steinwall M; Bossmar T; Serradeil-Le Gal C; Akerlund M
    Acta Obstet Gynecol Scand; 1998 Jan; 77(1):3-7. PubMed ID: 9492709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
    Stam WB; Van der Graaf PH; Saxena PR
    Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059.
    Serradeil-Le Gal C; Raufaste D; Marty E; Garcia C; Maffrand JP; Le Fur G
    Kidney Int; 1996 Aug; 50(2):499-505. PubMed ID: 8840278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
    Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
    Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits.
    Serradeil-Le Gal C; Villanova G; Boutin M; Maffrand JP; Le Fur G
    Fundam Clin Pharmacol; 1995; 9(1):17-24. PubMed ID: 7768483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
    Ammar A; Roseau S; Butlen D
    Am J Physiol; 1992 Apr; 262(4 Pt 2):F546-53. PubMed ID: 1533099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization and characterization of vasopressin binding sites in the rat brain using an iodinated linear AVP antagonist.
    Johnson AE; Audigier S; Rossi F; Jard S; Tribollet E; Barberis C
    Brain Res; 1993 Sep; 622(1-2):9-16. PubMed ID: 8242389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.